Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
X4 Pharmaceuticals, Inc (XFOR)
|
Add to portfolio |
|
|
|
| Price: |
$2.40
| | Metrics |
| OS: |
164.4
|
M
| |
|
|
| Market cap: |
$395
|
M
| |
|
|
|
Net cash:
|
$141
|
M
| |
$0.85
|
per share
|
|
EV:
|
$254
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-05-19 | Dec-31-18 | Dec-05-18 | Dec-31-17 |
| Revenues | 61.1 | 0.0 | 3.0 | 0.0 | 30.2 | 0.0 | 20.3 | 0.0 |
| Revenue growth | | -100.0% | | | 48.3% | | | |
| Cost of goods sold | 61.1 | 0.0 | 0.0 | 0.0 | 51.7 | 0.0 | 29.1 | 0.0 |
| Gross profit | 0.0 | 0.0 | 3.0 | 0.0 | -21.5 | 0.0 | -8.7 | 0.0 |
| Gross margin | 0.0% | | 100.0% | | -71.4% | | -43.0% | |
| Selling, general and administrative | 27.0 | | | | | | | |
| Research and development | | 50.6 | 41.9 | 30.2 | | 20.3 | | 17.1 |
| General and administrative | | 24.7 | 20.9 | 17.6 | 17.6 | 8.7 | 8.7 | 5.2 |
| EBIT | -87.6 | -75.3 | -59.9 | -47.8 | -51.7 | -29.1 | -29.1 | -22.2 |
| EBIT margin | -143.4% | | -1995.8% | | -171.4% | | -143.0% | |
| Pre-tax income | -93.8 | -88.7 | -62.0 | -52.8 | -52.8 | -33.3 | -33.3 | -22.0 |
| Income taxes | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -96.4 | -102.6 | -62.1 | -53.4 | -53.4 | -36.3 | -36.3 | -25.0 |
| Net margin | -157.9% | | -2071.0% | | -177.0% | | -178.4% | |
| |
| Diluted EPS | ($1.52) | ($3.99) | ($3.09) | ($4.63) | ($4.63) | ($79.10) | ($79.10) | ($54.57) |
| Shares outstanding (diluted) | 63.5 | 25.7 | 20.1 | 11.5 | 11.5 | 0.5 | 0.5 | 0.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|